// App-Quantinova.ai

POS1213 (2021) : IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN ON WELLBEING ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1)

Researchers

Presenter

  • M. Garrido-Cumbrera

Principal Investigators

  • H. Marzo-Ortega

  • L. Christen

  • L. Carmona

  • J. Correa-Fernndez

  • S. Sanz-Gomez

  • P. Plazuelo-Ramos

  • L. Grange

  • D. Webb

  • S. Irwin

  • C. Jacklin

  • S. Makri

  • E. Mateus

  • S. Mingolla

  • K. Antonopoulou

  • V. Navarro-Compn

Medical Centers

  • Universidad de Sevilla, Health & Territory Research (HTR), Seville, Spain

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds Biomedical Research Centre, Leeds, United Kingdom

  • Novartis Pharma AG, Patient Engagement, Basel, Spain

  • Institute for Musculoskeletal Health, Madrid, Spain

  • Spanish Federation of Spondyloarthritis Associations (CEADE), Presidency, Madrid, Spain

  • French League Against Rheumatism (AFLAR), Management, Grenoble, France

  • Centre Hospitalier Universitaire de Grenoble, Grenoble, France

  • National Axial Spondyloarthritis Society (NASS), Patient Advocacy, London, United Kingdom

  • Arthritis Action, Management, London, United Kingdom

  • National Rheumatoid Arthritis Society, Maidenhead, United Kingdom

  • Cyprus League Against Rheumatism (CYPLAR), Management, Nicosia, Cyprus

  • Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Management, Lisbon, Portugal

  • NOVA Medical School—Comprehensive Health Research Center (CHRC), Lisbon, Portugal

  • Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Communication, Bari, Italy

  • Hellenic League Againts Rheumatism (ELEANA), Management, Athens, Greece

  • Hospital Universitario La Paz, Madrid, Spain

Locations

  • Spain

  • United Kingdom

  • Switzerland

  • France

  • Cyprus

  • Portugal

  • Italy

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • Multinational

  • Cross-Sectional

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A